Peripheral Inflammatory Biomarkers as Predictors of Antidepressant Treatment Response in Major Depressive Disorder: An Updated Systematic Review and Meta-Analysis.
Ho Won Chun, Yeong Eun Park, Ju Hwan Kim et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the role of peripheral inflammatory biomarkers in predicting antidepressant response in adults with major depressive disorder (MDD). Analyzing 24 studies, the findings indicated that no baseline biomarkers significantly differentiated responders from non-responders. However, lower baseline IL-2 and IL-6 levels were associated with treatment response in recent studies (2021-2026) involving SSRIs and SNRIs.
Key findings
- No baseline biomarkers significantly differentiated responders from non-responders in primary analyses.
- Lower baseline IL-2 was associated with responders in recent studies (SMD = -0.81; p = 0.04).
- Lower baseline IL-6 was found in responders to SSRIs/SNRIs (SMD = -0.37; p = 0.02).
- Exploratory analyses indicated a nominal interaction by publication period for IL-2 (p = 0.0112).
Why it matters
Understanding the predictive value of inflammatory biomarkers could enhance treatment personalization in major depressive disorder, potentially improving outcomes by identifying patients more likely to respond to specific antidepressants.